| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Acetylcholinesterase and central nervous system targets. Buramate binds to the active site of acetylcholinesterase and blocks its activity. It has antipsychotic and anticonvulsant activity. The compound also has neuroprotective activity.
|
|---|---|
| ln Vitro |
Buramate binds to the active site of acetylcholinesterase and blocks its activity. It has antipsychotic and anticonvulsant activity. The compound also has neuroprotective activity. Buramate is a biodegradable analog of the amino acid L-phenylalanine and has been shown to be an effective inhibitor of muscle cell contraction.
|
| ln Vivo |
In vivo activity data for buramate is limited. The compound has antipsychotic and anticonvulsant activity and neuroprotective activity. Further in vivo studies are needed to fully characterize its therapeutic potential for neurological and psychiatric disorders.
|
| Enzyme Assay |
In vitro enzyme assays for buramate involve measuring its inhibition of acetylcholinesterase activity. Acetylcholinesterase is incubated with its substrate, acetylthiocholine, and various concentrations of buramate. The production of thiocholine is measured spectrophotometrically using Ellman's method. IC50 values are determined from concentration-response curves.
|
| Cell Assay |
In vitro cellular assays for buramate involve treating neuronal cells with the compound and measuring cell viability, neuroprotection, or acetylcholinesterase activity. Cells are treated with various concentrations of buramate, and cell viability is assessed by MTT or other metabolic assays. Neuroprotective effects are evaluated in models of excitotoxicity or oxidative stress.
|
| Animal Protocol |
In vivo animal studies for buramate typically involve administration to rodent models of seizures, psychosis, or neurodegeneration. Efficacy is assessed by measuring seizure frequency, behavioral changes, or neuroprotection. Buramate has anticonvulsant and antipsychotic activity. Further studies are needed to fully characterize its in vivo efficacy.
|
| ADME/Pharmacokinetics |
Buramate has a molecular weight of 195.22 and a molecular formula of C10H13NO3. It has a topological polar surface area of 58.6. The compound is a small-molecule carbamate derivative. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and elimination.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of buramate are limited. The compound has antipsychotic and anticonvulsant activity and has been studied for its neuroprotective effects. Comprehensive toxicological evaluation is needed before clinical development. The compound should be handled with appropriate safety precautions.
|
| Additional Infomation |
Buramate esters are a member of the benzene family of compounds.
Buramate (AC-601, Hyamate) is a small-molecule carbamate derivative with antipsychotic and anticonvulsant activity. It binds to the active site of acetylcholinesterase and blocks its activity. Buramate has neuroprotective activity and is a biodegradable analog of the amino acid L-phenylalanine. It is a valuable research compound for studying neurological and psychiatric disorders. |
| Molecular Formula |
C10H13NO3
|
|---|---|
| Molecular Weight |
195.22
|
| Exact Mass |
195.09
|
| CAS # |
4663-83-6
|
| PubChem CID |
20787
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.182 g/cm3
|
| Boiling Point |
375.8ºC at 760mmHg
|
| Flash Point |
181.1ºC
|
| Index of Refraction |
1.542
|
| LogP |
1.296
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
14
|
| Complexity |
167
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCCOC(NCC1C=CC=CC=1)=O
|
| InChi Key |
YFLRYAVDPKONNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13NO3/c12-6-7-14-10(13)11-8-9-4-2-1-3-5-9/h1-5,12H,6-8H2,(H,11,13)
|
| Chemical Name |
2-hydroxyethyl N-benzylcarbamate
|
| Synonyms |
AC601; AC 601; Buramate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1224 mL | 25.6121 mL | 51.2243 mL | |
| 5 mM | 1.0245 mL | 5.1224 mL | 10.2449 mL | |
| 10 mM | 0.5122 mL | 2.5612 mL | 5.1224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
